Review

Book

The $800 Million Pill: The Truth Behind the Cost of New Drugs

BMJ 2004; 329 doi: 10.1136/bmj.329.7465.577 (Published 2 September 2004)
Cite this as: BMJ 2004;329:577.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Jeff Aronson, reader in clinical pharmacology (jeffrey.aronson@clinpharm.ox.ac.uk)
  1. Oxford

    Two sets of statistics summarise the two main preoccupations of this book.


    Embedded Image

    Merrill Goozner

    University of California Press, $24.95/£16.95, pp 297 ISBN 0 520 23945 8 Also available as a digital download www.ucpress.edu/

    Rating: Embedded ImageEmbedded Image

    Firstly, the costs of drug development. The Tufts University Center for the Study of Drug Development calculated that in 2001 the pharmaceutical industry spent $802m (£446m; €663m) per marketed drug, while the Global Alliance for TB Drug Development thought that a new antituberculosis drug could be developed in the public sector for as little as $115m to $240m, conceding that the international …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular